Human tumour and dendritic cell hybrids generated by electrofusion: Potential for cancer vaccines

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1500, Issue 3, 2000, Pages 265-279

  Scott Taylor, T H ^a   Pettengell, R ^a   Clarke, I ^a   Stuhler, G ^b   La Barthe, M C ^a   Walden, P ^b   Dalgleish, A G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Cancer vaccine; Electrofusion; Human dendritic cell fusion; Hybrid cell

Indexed keywords

CANCER VACCINE;

ARTICLE; BREAST CELL; CELL FUSION; CONTROLLED STUDY; DENDRITIC CELL; DENSITY GRADIENT CENTRIFUGATION; DIRECT CURRENT; ELECTROSTIMULATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HYBRID CELL; PRIORITY JOURNAL; PROSTATE EPITHELIUM; TECHNIQUE; TUMOR CELL; VACCINE PRODUCTION;

CANCER VACCINES; CELL FUSION; CELL LINE; DENDRITIC CELLS; ELECTROPORATION; HUMANS; HYBRID CELLS; POLYETHYLENE GLYCOLS; TUMOR CELLS, CULTURED;

RODENTIA;

EID: 0034100236     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4439(99)00108-8     Document Type: Article

References (60)

1. Pardoll D.M. Cancer vaccines. Immunol. Today. 14:1993;310-316.
2. Houghton A.N. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1994;1-4.
3. Boon T., van der Bruggen P. Human tumour antigen recognised by T lymphocytes. J. Exp. Med. 183:1996;725-729.
4. Elliot B.E., Carlow D.A., Rodricks A.M., Wade A. Perspectives on the role of MHC antigens in normal and malignant cell development. Adv. Cancer Res. 53:1989;181-245.
5. Ruiz-Cabello F., Klein E., Garrido F. MHC antigens on human tumours. Immunol. Lett. 29:1991;181-189.
6. Cromme F.V., Airey J., Heemels M.T., Ploegh H.L., Keating P.J., Stern P.L., Meijer C.J., Walboomers J.M. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 179:1994;335-340.
7. Maeurer M.J., Colin S.M., Martin D., Swaney W., Bryant J., Castelli C., Robbins P., Parmiani G., Storkus W.J., Lotze M.T. Tumour escape from immune recognition: lethal recurrent melanoma on a patient associated with downregulation of the peptide transporter protein TAP-1 and the loss of the immunodominant MART-1/Melan-A antigen. J. Clin. Invest. 98:1996;1633-1641.
8. Seliger B., Maeurer M.J., Ferrone S. TAP off-Tumour on. Immunol. Today. 18:1997;292-299.
9. Chen L., Ashe S., Brady W.A., Hellstrom I., Hellstrom K.E., Ledbetter J.A., McGowan P., Linsley P.S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocye molecules CD28 and CTLA-4. Cell. 71:1992;1093-1102.
10. Townsend S.E., Allison J.P. Tumor rejection after direct stimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 259:1993;368-370.
11. Restifo N.P., Esquivel F., Kawakami Y., Yewdell J.W., Mule J.J., Rosenburg S.A., Bennink J.R. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177:1993;265-272.
12. Sanda M.G., Restifo N.P., Walsh J.C., Kawakami Y., Nelson W.G., Pardoll D.M., Simons J.W. Molecular characterization of defective antigen presentation in human prostate cancer. J. Natl. Cancer Inst. 87:1995;241-243.
13. Gong J., Chen D., Kashiwaba M., Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carinoma cells. Nat. Med. 3:1997;558-561.
14. Guo Y., Wu M., Chen H., Wang X., Liu G., Li G., Ma J., Sy M-S. Effective tumour vaccine generated by fusion of hepatoma cells with activated B cells. Science. 263:1994;518-520.
15. Stuhler G., Trefzer U., Walden P. Hybrid cell vaccination in cancer immunotherapy. Recruitment and activation of T cell help for induction of anti tumour cytotoxic T cells. Adv. Exp. Med. Biol. 451:1998;277-282.
16. Steinman R.M. Dendritic cells and immune-based therapies. Exp. Hematol. 24:1996;859-862.
17. Inaba K., Metlay J.P., Crowley M.T., Steinman R.M. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J. Exp. Med. 172:1990;631-640.
18. Young J.W., Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 183:1996;7-11.
19. Grabbe S., Beissert S., Schwarz T., Granstein R.D. Dendritic cells as initiators of tumour immune responses: a possible strategy for tumor immunotherapy? Immunol. Today. 16:1995;117-121.
20. Lanzavecchia A. Identifying strategies for immune intervention. Science. 260:1993;937-944.
21. Nair S.K., Boczkowski D., Morse M., Cumming R.I., Lyerly H.K., Gilboa E. Induction of primary carcinoembyronic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol. 16:1998;364-369.
22. Celluzzi C.M., Falo L.D. Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity. J. Invest. Dermatol. 108:1997;716-720.
23. Song W., Kong H.L., Carpenter H., Torii H., Granstein R., Rafii S., Moore M.A., Crystal R.G. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186:1997;1247-1256.
24. De Veerman M., Heirman C., Van Meirvenne S., Devos S., Corthlas J., Moser M., Theilmans K. Retrovirally transduced bone-marrow derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. J. Immunol. 162:1999;144-151.
25. Kohler G., Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur. J. Immunol. 6:1976;511-519.
26. Jaroszeski M.J., Gilbert R., Fallon P.G., Heller R. Mechanically facilitated cell-cell electrofusion. Biophys. J. 67:1994;1574-1581.
27. Jaroszeski M.J., Heller R., Gilbert R. Detection and quantitation of cell-electrofusion products by flow cytometry. Anal. Biochem. 216:1994;271-275.
28. Li L.H., Henson M.L., Zhao Y.L., Hui S.W. Electrofusion between heterogenous-sized mammalian cells in a pellet: potential applications in drug delivery and hybridoma formation. Biophys. J. 71:1996;479-486.
29. Zimmerman U. Electric field-mediated fusion and related electrical phenomena. Biochim. Biophys. Acta. 694:1982;227-277.
30. Murphy G., Tjoa B., Ragde H., Kenny G., Boynton A. Phase I clinical trial T cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A201-specific peptides from prostate specific membrane antigen. Prostate. 29:1996;371-380.
31. Lotze M.T., Hellerstedt B., Stolinski L., Tueting T., Wilson C., Kinzler D., Vu H., Rubin J.T., Storkus W., Tahara H., Elder E., Whiteside T. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J. Sci. Am. 3:1997;S109-114.
32. Salgaller M.L., Tjoa B.A., Lodge P.A., Ragde H., Kenny G., Boynton A., Murphy G.P. Dendritic cell-based immunotherapy of prostate cancer. Crit. Rev. Immunol. 18:1998;109-119.
33. Tjoa B.A., Erikson S.L., Bowes V.A., Ragde H., Kenny G.M., Cobb O.E., Ireton R.C., Troychak M.J., Boynton A.I., Murphy G.P. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate. 32:1997;272-278.
34. Neil G.A., Zimmermann U. Electrofusion. Methods Enzymol. 220:1993;174-246.
35. Abidor I.G., Sowers A.E. Kinetics and mechanism of cell membrane electrofusion. Biophys. J. 61:1992;1557-1569.
36. Wojcieszyn J.W., Schlegel R.A., Lumley-Sapanski K., Jakobson K.A. Studies on the mechanism of polyethylene glyco-induced cell fusion using fluorescent and cytoplasmic probes. J. Cell Biol. 96:1983;151-159.
37. Sowers A.E. Characterization of electric field-induced fusion of erythrocyte ghost membranes. J. Cell Biol. 99:1988;1989-1996.
38. Song L.Y., Ahkong Q.F., Baldwin J.M., O'Reilly R., Lucy J.A. Divalent cations, phospholipid asymmetry and osmotic swelling in electrically-induced lysis, cell fusion and giant cell formation with human erythrocytes. Biochim. Biophys. Acta. 1148:1993;30-38.
39. A.E. Sowers, The study of membrane fusion and electroporation mechanisms. In: M.J. Allem, S.F. Cleary, F.M. Hawkridge (Eds.), Charge and Field Effects in Biosystems, Vol. 2, Plenum Press, New York, 1989, pp. 315-337.
40. Kramer I., Vienken K., Vienken J., Zimmermann U. Magneto-electro-fusion of human erythrocytes. Biochim. Biophys. Acta. 772:1984;407-410.
41. Bertsche U., Mader A., Zimmermann U. Nuclear membrane fusion in electrofused mammalian cells. Biochim. Biophys. Acta. 939:1988;509-522.
42. Teissie J., Knutson V.P., Tsong T.Y., Lane M.D. Electrical pulse-induced fusion of 3T3 cells in monolayer culture. Science. 216:1982;537-538.
43. Lo M.M.S., Tsong T.Y., Conrad M.K., Strittmatter S.M., Hester L.D., Snyder S.H. Monoclonal antibody production by receptor-mediated electrically induced cell fusion. Nature. 310:1984;792-794.
44. Wojchowski D.M., Sytkowski A.J. Hybridoma production by simplified avidin-mediated electrofusion. J. Immunol. Methods. 90:1986;173-177.
45. Stoicheva N.G., Hui S.W. Electrically induced fusion of mammalian cells in the presence of polyethylene glycol. Membrane Biol. 140:1994;177-182.
46. Li L.H., Hui S.W. Characterization of PEG-mediated electrofusion of human erythrocytes. Biophysical J. 67:1994;2361-2366.
47. Finaz C., Lefevre A., Teissie J. A new, highly efficient technique for generating somatic cell hybrids. Biochim. Biophys. Acta. 1023:1984;389-397.
48. Sukharev S.I., Bandrina I.N., Barbul A.I., Fedorova L.I., Abidor I.G., Zelenin A.V. Electrofusion of fibroblasts on the porous membrane. Biochim. Biophys. Acta. 1034:1990;125-131.
49. Ohno-Shosaku T., Okada Y. Facilitation of electrofusion of mouse lymphoma cells by the proteolytic action of proteases. Biochem. Biophys. Res. Commun. 120:1984;138-143.
50. Stenger D.A., Hui S.W. Kinetics of ultrastructure changes during electrically induced fusion of human erythrocytes. J. Membr. Biol. 93:1986;43-53.
51. Schmitt J.J., Zimmermann U., Niel G.A. Efficient generation of stable antibody forming hybridoma cells by electrofusion. Hybridoma. 8:1989;107-115.
52. Zhelev D.V., Dimitrov D.S., Dionov P. Correlation between physical parameters in electrofusion and electroporation of protoplasts. Bioelectrochem. Bioenerg. 20:1988;155-167.
53. Stoicheva and Hui (1994).
54. Robinson J.M., Roos D.S., Davidson R.L., Karnovsky M.J. Membrane alterations and other morphological features observed with polyethylene glycol-induced cell fusion. J. Cell Sci. 40:1979;63-75.
55. Hui S.W., Isac T., Boni L.T., Sen A. Action of polyethylene glycol on the fusion of human erythrocyte membranes. J. Membr. Biol. 84:1985;137-146.
56. Benz R., Zimmermann U. The resealing process of lipid bilayers after reversible electrical breakdown. Biochim. Biophys. Acta. 640:1981;169-178.
57. Tiessie J., Rols M.P. Fusion of mammalian cells in culture is obtained by creating the contact between cells after their electropermeabilization. Biochem. Biophys. Res. Commun. 140:1986;258-266.
58. Sowers A.E. A long-lived fusogenic state is induced in erythrocyte ghosts by electric pulses. J. Cell Biol. 102:1986;1358-1362.
59. Romani N., Reider D., Heuer M., Kampgen E., Eibl B., Niederwieser D., Schuler G. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods. 196:1996;137-145.
60. Zhou L-J., Tedder T.F. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc. Natl. Acad. Sci. USA. 93:1996;2588-2594.